Notably, ERRα inhibitors have also shown potential in breast cancer risk prevention and mitigation through disruption of cancer cell metabolism, proliferation, and tumor growth by interfering with genes associated with oncogenic processes [39,61,62]. Here, ESRRA is linked to breast cancer.